Pfizer announces acceptance of regulatory submission for inotuzumab ozogamicin by the U.S. Food and Drug Administration. Pfizer Inc. announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). Inotuzumab ozogamicin is being evaluated for the treatment of adult patients…